MedTrace Logo

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

NCT00826241 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2019-03-22

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.

Conditions

Interventions

DRUG

Temozolomide

Starting dose 125 mg/m\^2 daily by mouth on days 1-7 \& 15-21 of a 28 day cycle.

DRUG

Lapatinib

Starting dose 1250 mg daily by mouth.

Sponsors & Collaborators

  • CERN Foundation - Collaborative Ependymoma Research Network

    collaborator NETWORK

  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • Marta Penas-Prado, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2018-07-31
Completion
2018-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00826241 on ClinicalTrials.gov